clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wheeldon TU et al. | The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. | 2004 | Aliment. Pharmacol. Ther. | pmid:15191514 |
Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
Datta S et al. | Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963080 |
Perri F et al. | Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421877 |
Perri F et al. | Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421878 |
Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
Kaneko F et al. | High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298607 |
Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
Chiba N et al. | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:14984382 |
de Francesco V et al. | Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423002 |
Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
Wong BC et al. | One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207516 |
Fakheri H et al. | Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207517 |
Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
Fischbach LA et al. | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569109 |
Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
Tomita T et al. | Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966543 |
Vakil N et al. | Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. | 2008 | Aliment. Pharmacol. Ther. | pmid:18774949 |
Peitz U et al. | High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860415 |
Qasim A and O'Morain CA | Review article: treatment of Helicobacter pylori infection and factors influencing eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849124 |
Sheu BS et al. | Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:12197847 |
Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
Vakil N et al. | Seven-day therapy for Helicobacter pylori in the United States. | 2004 | Aliment. Pharmacol. Ther. | pmid:15225176 |
Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
Basset C et al. | Helicobacter pylori infection: anything new should we know? | 2004 | Aliment. Pharmacol. Ther. | pmid:15335411 |
Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
Calvet X et al. | A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10792124 |
Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
Goh KL et al. | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? | 1997 | Aliment. Pharmacol. Ther. | pmid:9663838 |
Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
Pilotto A et al. | The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233191 |
Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
Lionetti E et al. | Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:17032283 |
Laurent J et al. | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683693 |
Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
Malfertheiner P et al. | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752349 |
Gené E et al. | Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752350 |
Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
Canducci F et al. | A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121911 |
Toracchio S et al. | Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121913 |
You JH et al. | Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421876 |
Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
Gisbert JP et al. | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. | 2006 | Aliment. Pharmacol. Ther. | pmid:16556172 |
Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
Sengupta S et al. | Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803607 |
Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
Rinaldi V et al. | The management of failed dual or triple therapy for Helicobacter pylori eradication. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354202 |
Breuer T et al. | Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354204 |
Wurzer H et al. | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354205 |
Harris A | H. pylori eradication by LAC. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354216 |
Osato MS et al. | Comparative efficacy of new investigational agents against Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284777 |
Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
Savarino V et al. | A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. | 1997 | Aliment. Pharmacol. Ther. | pmid:9305478 |
Yousfi MM et al. | Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). | 1996 | Aliment. Pharmacol. Ther. | pmid:8871452 |
Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
Peterson WL et al. | Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791947 |
Delchier JC et al. | Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791948 |
Jaup BH and Norrby A | Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791950 |
Ott EA et al. | Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882244 |
Weldon MJ et al. | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791951 |
Tursi A et al. | Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791952 |
Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
Gisbert JP et al. | Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. | 2005 | Aliment. Pharmacol. Ther. | pmid:16268980 |
Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
Miwa H et al. | Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? | 2003 | Aliment. Pharmacol. Ther. | pmid:12823158 |
Armuzzi A et al. | The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11148433 |
Harris AW et al. | Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971302 |
Moshkowitz M et al. | One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971304 |
Laine L et al. | Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971306 |
McNulty CA et al. | Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? | 2012 | Aliment. Pharmacol. Ther. | pmid:22469191 |